Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Sep 18, 2014)
  • 8-K (Sep 2, 2014)
  • 8-K (Aug 29, 2014)
  • 8-K (Aug 13, 2014)
  • 8-K (Aug 5, 2014)
  • 8-K (Jul 1, 2014)

 
Other

BioCryst Pharmaceuticals 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic
Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 16, 2012

 

 

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-23186   62-1413174

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(Registrant’s telephone number, including area code): (919) 859-1302

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 16, 2012, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) elected Nancy J. Hutson, Ph.D., to the Company’s Board of Directors effective January 20, 2012. The Company issued a news release reporting this matter on January 19, 2012, and a copy of the news release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The Company’s Board of Directors has not yet appointed Ms. Hutson to serve on any of its committees.

Pursuant to the Company’s Stock Incentive Plan, Ms. Hutson will receive an automatic grant of 8,333 stock options upon joining the Board of Directors, and will be entitled to a grant of 15,000 stock options after each annual stockholders’ meeting. Ms. Hutson will receive compensation consistent with the Company’s director compensation policy as described in the Company’s proxy statement for its 2011 annual meeting of stockholders.

 

Item 7.01 Regulation FD Disclosure

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information furnished is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.

  

Description

99.1    Press release dated January 19, 2012 entitled “Nancy Hutson Appointed to BioCryst’s Board of Directors”


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

BioCryst Pharmaceuticals, Inc.
By:  

/s/ Alane Barnes

  Name:   Alane Barnes
  Title:   General Counsel, Corporate Secretary

Date: January 20, 2012


INDEX TO EXHIBITS

 

Exhibit
No.

  

Description

99.1    Press release dated January 19, 2012 entitled “Nancy Hutson Appointed to BioCryst’s Board of Directors”
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki